Neurology

In instances when longer term treatment is required, continued use of IG should be based on objective measures of effectiveness established at the outset of treatment. These measures should be assessed no later than 6 months after initiation of treatment and at least annually thereafter. If clinical effectiveness has not been achieved, IG should be discontinued.

Neuropathic pain

Do Not Use

Neuropathy associated with IgM paraproteinemia

Recommended Indications in which IG can be used

Order Number: N10-NAIgMP

Opsoclonus-Myoclonus Ataxia (OMA) – pediatric onset

Recommended Indications in which IG can be used

Order Number: N11-OMA

Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)

Not for Routine Use

Order Number: N16- PANDAS

Polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, skin changes (POEMS) syndrome

Do Not Use

Post-polio syndrome

Do Not Use

Rasmussen’s encephalitis

Not for Routine Use

Order Number: N17-RE

Sjögren syndrome associated neuropathy

Recommended Indications in which IG can be used

Order Number: N12-SSN

Stiff Person Syndrome (Moersch–Woltman syndrome)

Recommended Indications in which IG can be used

Order Number: N13-MWS

Sydenham chorea

Recommended Indications in which IG can be used

Order Number: N14-SC